OPINION Mechanistic insights from combining genomics with metabolomics
INTRODUCTION
Metabolomics is the study of the quantitative complement of small molecules in biological systems. The metabolic variables measured are mostly organic compounds, involved in the biochemical reactions of the organism and represent the final stage of the flow of information from the genome to the transcriptome and then to the proteome before it reaches the biological phenotype [1] . But unlike the genes and proteins, that can be subjected to epigenetic or post-translational changes, the metabolites provide a direct signature of biochemical activity and a snapshot of the underlying state of the organism or specific biological system sampled [2] . In the case of lipids, lipidomics, a subfield of metabolomics, can measure not only the larger groupings of lipids and lipoproteins, commonly assessed in the clinic, such as HDL, LDL, triglycerides, and total cholesterol, but also specific lipoprotein subclasses both in terms of concentration and composition, as well as a large number of other lipid compounds involved in numerous physiological processes or biological structures. The measurements obtained from the metabolomics approaches can be used to study the relationships between the metabolites or used to better characterize a complex biological mechanism.
Genomics study the function of the genome and its role in the manifestation of the organism's characteristics or risk of disease. The genome can be divided in a protein coding part, known as the exome, and the much larger noncoding part. Changes in both have been associated with a number of diseases or phenotypic changes in humans and other organisms. Very large efforts have focused on cataloguing all functional variation present in the genome, either in coding [3, 4] or noncoding regions [5] . Despite these efforts and the large quantity of data currently available, in the majority of cases, we are still unsure how a DNA change results in changes in the observed phenotype.
As metabolomics represent phenotyping at the molecular level that extends closer to the biological processes taking place in the organism, which are mostly coded by the genome, the integration of the two levels of information can provide the opportunity to better study biological mechanisms and determine how they result in a final phenotypic change or disease.
METABOLIC TRAITS GENOME-WIDE ASSOCIATION
The most straightforward method to combine metabolomics with genomics is the use of a metabolic trait genome-wide association study (mGWAS). Unlike studies trying to uncover associations with a risk factor or disease endpoint, mGWAS usually identify associations that point directly to specific underlying biological mechanisms [6] . Commonly, multiple metabolites are tested in parallel mGWAS, either based on a preselection of a small number of metabolites or using the whole set of available metabolites. For instance, trying to identify endogenous molecules and genetic factors affecting lean mass, Korostishevsky et al. [7] performed an association analysis between a lean muscle phenotype and an array of metabolic measures. They then selected the top three associated metabolites, explaining 11% of the variation of the trait, to run the mGWAS. One of the three metabolites used, X12063, was found to be associated with polymorphisms in the CYP3A5 and SLCO1B1 genes (coding for Cytochrome P450 3A5 and Solute carrier organic anion transporter family member 1B1 proteins, respectively). Both of these loci have previously been associated with statin uptake and efficacy; statins are well known for their muscle related side-effects [8] . Unfortunately, X12063 is currently an unknown metabolite, but based on its associations with these two genes we will hopefully soon be able to characterize it and further understand the link between statins and myopathies.
CHARACTERIZING THE METABOLIC IMPACT OF GENES
A more common use of mGWAS is to provide functional characterization of specific genes and to allow us to better understand the relevant pathways. This is closer to what is commonly described as a phenome scan, in this case a metabolome scan, where a locus of interest is tested for association with multiple phenotypes, here metabolites or metabolic measures. In an illustrative example, using results from 129 mGWAS, Draisma et al. [9] , found 31 loci associated with 85 different metabolites. The FADS1-3 gene cluster, coding for the fatty acid desaturase 1 to 3 proteins, showed the largest number of associations, with 12 single-nucleotide polymorphism (SNPs) at the locus associated with 47 of the metabolites tested, all of which were glycerophospholipids. SNPs in the locus have also been associated with plasma levels of LDL, HDL, total cholesterol, and triglycerides [10, 11] , as well as with polygenic dyslipidaemia [12] . The function of the genes in the cluster is to introduce double bonds during the desaturation of fatty acids. The glycerophospholipids measured were both upstream and downstream of the enzymatic action of the gene products and their changes reflected the known metabolic pathway steps [13] . According to these results, the balance between glycerophospholipids and the availability of polyunsaturated long-chain fatty acids with four or more double bonds has the potential to alter the levels of cholesterol, triglycerides, and associated lipoproteins. Furthermore, the close agreement between what is known for the function of the FADS1-3 cluster of genes from biochemical studies and the metabolomics results obtained from population samples, through the combination of genetic and metabolomics data, provides a perfect illustration of the power of this method to gain insights into biological processes in vivo, which were otherwise hidden from observational epidemiology.
Insights into lipoprotein (a) composition
In another example of mGWAS use, Kettunen et al. [14 && ] tested the genome-wide associations of 123 metabolic measures focusing on the characterization
KEY POINTS
Metabolomics measure the molecular phenotype of the biological processes taking place in the organism.
Parallel metabolic trait genome-wide association analyses are currently used to describe the functional mechanisms of genes and elucidate the corresponding pathways.
Multiomics approaches make use of metabolomics in combination with genomics and transcriptomics to present a system-wide picture of the relationships between metabolites.
A number of challenges remain, mainly around the portion of the metabolome captured and the compatibility of the measures obtained from different platforms, which need to be addressed for the wider use of these data.
of the LPA gene. LPA codes for lipoprotein (a) [Lp(a)], a well established coronary heart disease (CHD) risk factor [15] . Elevated levels of Lp(a) are believed to increase the risk of cardiovascular disease through the inhibition of fibrinolysis and the promotion of coagulation [15] . In addition to the already known associations with LDL and triglycerides, the analysis of the metabolic measures revealed strong associations of Lp(a) with the diameter and concentration levels of the larger VLDL particles [14 && ,16] . Using a gene score, accounting for 45% of the Lp(a) variance in the sample used, to summarize the total effect of the associated LPA polymorphisms on Lp(a) protein, the authors repeated the analysis of the metabolic measures obtaining similar results, with the diameter of the VLDL particles being the top signal. Comparing the pattern and estimates of the associations of the Lp(a) protein levels to the metabolites and the associations of the LPA polymorphisms on the same metabolites suggested a causal effect of Lp(a) on the relevant VLDL measures. Based on these results, the authors suggested that the apolipoprotein B (apoB)-containing lipoprotein particle, which covalently binds to apo(a) for the formation of Lp(a), may also be a poorly lipidated VLDL type of particle, challenging the idea that Lp(a) is just an apo(a) component added to LDL particles [14 && ].
The function of apo-CIII and its LPL independent role
The use of metabolomics to characterize rare genetic variants altering the structure or function of a coded protein, provides us with an even better direct view of the relevant biological mechanisms operating within an organism. Apo C-III is involved in a number of intra and extracellular mechanisms, including the production and clearance of triglyceride-rich lipoproteins. Polymorphisms in the Apolipoprotein C-III coding (APOC3) gene locus have been previously robustly associated with levels of plasma triglycerides, HDL, and VLDL as well as with risk of CHD [10, [17] [18] [19] [20] [21] . A rare loss of function mutation in the APOC3 gene, rs138326449 (IVS2þ1G>A), significantly lowers the risk of CHD by approximately 40% [17, 19] . The same mutation was tested against 225 metabolic measures, including the size and composition of 14 lipoprotein subclasses in 13 285 participants from two European population cohorts [22 & ]. In addition to the previously reported associations, the variant was also strongly associated with VLDL and HDL composition measures, other cholesterol measures and fatty acids. The effect of apo C-III on lipids is believed to operate through the inhibition of triglyceride-rich lipoproteins hydrolysis by lipoprotein lipase (LPL), which in turn lowers their uptake from the hepatocytes. Under this model, the decrease in VLDL and increase of HDL concentrations were because of the loss of function mutation permitting a faster LPL-mediated rate of hydrolysis. To test this hypothesis, the common LPL SNP, and leading GWAS association SNP in the locus, rs12678919, was tested for association with the 225 metabolic measures. The results confirmed that the two polymorphisms, within APOC3 and LPL genes, had the same general pattern of associations, providing additional support for the standard model. Mathematical modelling of the individual SNP-measures associations revealed, however, that this is not true for all lipid traits tested. The triglyceride content of very large and medium VLDL particles was lower than expected if the effect was solely through LPL inhibition. VLDL is produced in the hepatocytes through a complex process, not yet fully understood, where apo B-100 is combined with triglyceride and other apolipoproteins and cholesteryl esters [23, 24] . In cell cultures and model organisms under insulin resistance or hypertriglyceridemia, apo C-III facilitates the binding of triglycerides to pre-VLDL molecules. Specific changes in apo C-III affect the composition of larger VLDL particles but not the less triglyceridesrich smaller VLDL [24] . Although the metabolic associations in this instance refer to changes in the plasma VLDL composition, it is possible that they reflect the end product of an intracellular process affecting the assembly and secretion of the larger VLDL particles. The results also suggest that the role of apo C-III in the cell, although noticeable under specific conditions during which the liver is trying to remove stored triglycerides, is continuously active. However, the contribution of the LPL-independent pathway to the overall circulating levels of VLDL and triglycerides is rather limited under normal conditions in comparison with the LPL-dependent pathway. The same intracellular apo C-III-dependent mechanism might also contribute to the effect of the APOC3 antisense oligonucleotide inhibitor volanesorsen (ISIS 304801), which showed promising results in lowering triglycerides levels in patients with both severe hypertriglyceridemia and familial chylomicronemia syndrome [25, 26] .
METABOLOMICS IN MULTIOMICS APPROACHES
The greatest promise of metabolomics lies in accounting for the organization of the metabolites in defined pathways, or groups, and combining this information with genomics or other omics technologies. Various metabolomics-based methods considering metabolites, not just in isolation, but organized in pathways, are currently in use. These & ]. The pathway information can then be used to test for association with a gene, or group of genes, describing the biological mechanism of interest. An example of such an approach can be found in Ried et al. [29] who used a phenotype set enrichment analysis to test for overrepresentation of sets of metabolites at genes. Their results suggested that genes of the cytochrome P450 family 4 are involved in reactions that use glycerolipids and fatty acids as substrates, haem as a cofactor and carnitines as related compounds.
Even more information on the underlying molecular mechanisms can be obtained from metabolomic and genomic data by incorporating additional omics results. Recently, Bartel et al. [30 & ] combined whole blood transcriptomics with metabolomics and used the genomic information to test the causal relationships between transcripts and metabolites. Further integration with external database information allowed the identification of systematic signatures of lipid, energy, and amino acid metabolic reactions. Using the derived functional categories in a network representation of the system, pathways activated in a coordinated manner were observed. Finally, the measured metabolites, transcripts, metabolic pathways, and gene annotation terms were used to identify novel associations between the molecular mechanisms inferred and the common CHD risk factors of HDL, LDL, and triglycerides. An antagonistic pattern of associations between HDL and triglycerides was observed for parts of the model where coregulation was evident. Interestingly, a regulatory mechanism involving the sterol regulatory elementbinding genes was found to link HDL, triglycerides, and branched-chain amino acids at a transcriptional level. A negative association between HDL and the 'gamma-glutamyl metabolism' pathway was also identified, which was similar to the reported association between a Glutamate-Ammonia Ligase gene polymorphism, encoding for the glutamine-synthase enzyme, and HDL [31] . The later though was seen only in those with type 2 diabetes, so the proposed mechanism might actually be more complex than we currently think and might involve other metabolites and higher order interactions.
PRESENT CHALLENGES AND LIMITATIONS
The integration of metabolomics with other omics data, and most importantly genomics, is key to the fulfilment of the metabolomics promise for precision medicine [32] . The data allowing such multilevel approaches have only recently started to become available in a scale that permits wellpowered epidemiological studies with independent replication. However, a number of limitations are starting to also become obvious. There is no reliable estimate on how big the human metabolome is. We are currently able to measure and provide quantification for hundreds of known metabolites and relative quantification for thousands of known and unknown measures from biological samples such as blood and urine [32] . The Human Metabolome Database (http://www.hmdb.ca/) has catalogued 42 003 metabolites with just 5701 linked to protein sequences, though more are expected to exist. Currently, there is no single method that can provide a comprehensive measurement of all the known metabolites. The identification of the large number of unnamed metabolites is still an issue, which requires substantial effort. Methods to predict what an unnamed metabolite is are available, but they still require laboratory verification, which is not always easy [33] . There is also significant fragmentation between the laboratory and computational methods used to obtain, interpret, and quantify raw metabolomics data. The majority of these methods are protected behind intellectual property rights [34] that make standardization difficult. A recent effort to compare 43 common metabolites from two platforms in the same individuals found that their mean correlation was just 0.44, though some showed very high agreement and some almost none [35] . All these issues are expected to be resolved in the next few years as metabolomics technology matures and new standards emerge.
CONCLUSIONS
Despite the limitations, the integration of metabolomics with genomics has already provided a wealth of new information on the function of genes that have been previously associated with important diseases and the pathways through which they exert their effects. Use of additional omics to further enrich the available information will be the key for the complete understanding of the biological mechanisms maintaining human health. This multiomics view though will also require sustained crossfield collaborations and a new generation of scientists who can communicate across fields as diverse as chemistry, epidemiology and computer science. Only when the integration of the data is supported by an equal integration of ideas will we start to translate the current abundance of data to the patients' benefit.
